White House Wants to Gut NIH, Allergan’s CRISPR Foray, & New VCs Sprout Up

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.